Efficacy & safety of Ivabradine versus Beta blocker in Inappropriate Sinus Tachycardia
Not Applicable
- Conditions
- Health Condition 1: R000- Tachycardia, unspecified
- Registration Number
- CTRI/2023/06/054179
- Lead Sponsor
- Kasturba Medical College, Manipal
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients diagnosed with IST (resting daytime sinus rate of more than 100 beats per minute and/or average 24-h Holter ECG HR of more than 90 beats per minute) by the treating physician and started on ivabradine or beta blockers during the study period
Exclusion Criteria
Secondary causes of sinus tachycardia (including anaemia, hyperthyroidism, infections, hypovolemia, or drugs), previous atrial or ventricular arrhythmias (i.e. atrial fibrillation/flutter, supraventricular arrhythmias, nonsustained or sustained ventricular arrhythmias), structural heart diseases, postural orthostatic tachycardia syndrome, sinus nodal re-entrant tachycardia
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To Determine & Compare the reduction in resting HR & peak HR of Inappropriate Sinus TachycardiaTimepoint: At follow up after one month
- Secondary Outcome Measures
Name Time Method 1) To study demographic profile of IST patients <br/ ><br>2) Collection of Adverse Drug Reactions (ADRs reported) <br/ ><br>3) Pharmacoeconomic evaluation of the treatments using a suitable model <br/ ><br>4) To assess the quality of life using European Heart Association EHRA score & SF-36 questionnaire <br/ ><br>Timepoint: At end of study